Limited proteolysis
- PapersOthers（Reference ducuments）Limited proteolysis
-
Kimura et al.(2022) [nSMOL]
Microvolume Analysis of Aflibercept in Aqueous Humor Using Mass Spectrometry
Translational Vision Science & Technology June 2022, Vol.11, 7
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2022) [nSMOL]
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2022) [nSMOL]
Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies
Methods Mol Biol. 2022;2313:187-205
- PapersOthers（Reference ducuments）Limited proteolysis
-
Nakae et al.(2021) [nSMOL]
- PapersOthers（Reference ducuments）Limited proteolysis
-
M. Ohuchi et al. (2021) [nSMOL]
Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species
Journal of Chromatography B 1162 (2021) 122489
- PapersOthers（Reference ducuments）Limited proteolysis
-
Koguchi et al.(2021) [nSMOL]
- PapersOthers（Reference ducuments）Limited proteolysis
-
Brendan D Curti et al.(2021) [nSMOL]
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
J Immunother Cancer 2021;9:e002371
- PapersOthers（Reference ducuments）Limited proteolysis
-
K. Todoroki et al. (2020) [nSMOL]
Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates: A review of recent advances and future perspectives
Journal of Pharmaceutical and Biomedical Analysis 179 (2020) 112991
- PapersOthers（Reference ducuments）Limited proteolysis
-
L. Kong et al. (2020) [nSMOL]
A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously
Analytical and Bioanalytical Chemistry 412 (2020) 1003
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2019) [nSMOL]
Acceleration of nano-surface and molecular-orientation limited(nSMOL) proteolysis with acidified reduction pretreatment forquantification of Tocilizumab
Journal of Pharmaceutical and Biomedical Analysis 164 (2019) 467–474
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2019) [nSMOL]
- PapersOthers（Reference ducuments）Limited proteolysis
-
Masui et al.(2019) [nSMOL]
Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report
Journal of Pharmaceutical Health Care and Sciences (2019) 5:9
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2019) [nSMOL]
Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
J. Immunol. Methods, 472, 44(2019)
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2019) [nSMOL]
Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach
Drug Metabolism and Pharmacokinetics 34, 19 (2019)
- PapersOthers（Reference ducuments）Limited proteolysis
-
Dawei Bu et al.(2019) [nSMOL]
Human endotrophin as a driver of malignant tumor growth
JCI Insight. 2019;4(9):e125094
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2018) [nSMOL]
Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis
Analytical Biochemistry 540–541 (2018) 30–37
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2018) [nSMOL]
Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies
Pharmacology and Therapeutics 185, 147 (2018)
- PapersOthers（Reference ducuments）Limited proteolysis
-
Iwamoto et al.(2018) [nSMOL]
Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum
Current Pharmaceutical Biotechnology, 2018, 19, 495-505
- PapersOthers（Reference ducuments）Limited proteolysis
-
Iwamoto et al.(2018) [nSMOL]
Application of nSMOL coupled with LC‐MS bioanalysis for monitoring the Fc‐fusion biopharmaceuticals Etanercept and Abatacept in human serum
Pharmacol Res Perspect. 2018;e00422
- PapersOthers（Reference ducuments）Limited proteolysis
-
Vialaret et al.(2017) [nSMOL]
What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
Bioanalysis. 2018 May 1;10(10):723-735
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2017) [nSMOL]
LC–MS bioanalysis of Trastuzumab and released emtansine usingnano-surface and molecular-orientation limited (nSMOL) proteolysisand liquid–liquid partition in plasma of Trastuzumabemtansine-treated breast cancer patients
Journal of Pharmaceutical and Biomedical Analysis 145 (2017) 33–39
- PapersOthers（Reference ducuments）Limited proteolysis
-
Matsumaru et al.(2017) [nSMOL]
The 8th Japan Bioanalysis Forum symposium
Bioanalysis (2017) 9(22), 1733–1737
- PapersOthers（Reference ducuments）Limited proteolysis
-
Chiu et al.(2017) [nSMOL]
Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma.
Analytical and Bioanalytical Chemistry
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al.(2016) [nSMOL]
Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nanosurface and Molecular-Orientation Limited (nSMOL) Proteolysis
Biol. Pharm. Bull. 39, 1187–1194 (2016)
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2016) [nSMOL]
Validated LC–MS/MS analysis of immune checkpoint inhibitorNivolumab in human plasma using a Fab peptide-selectivequantitation method: nano-surface and molecular-orientation limited(nSMOL) proteolysis
Journal of Chromatography B, 1023-1024 (2016) 9–16
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al.(2016) [nSMOL]
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2016) [nSMOL]
Application of nano-surface and molecular-orientation limited proteolysis to LC?MS bioanalysis of cetuximab.
Bioanalysis, 8, 1009 (2016).
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2016) [nSMOL]
Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis
Drug Metab. Pharmacokinet., 31, 46 (2016).
- PapersOthers（Reference ducuments）Limited proteolysis
-
Iwamoto et al.(2015) [nSMOL]
- PapersOthers（Reference ducuments）Limited proteolysis
-
N. Iwamoto et al. (2014) [nSMOL]
